Publicaciones en las que colabora con Jesús Egido de los Ríos (25)

2024

  1. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease

    International Journal of Molecular Sciences, Vol. 25, Núm. 5

2021

  1. Bisphenol S is a haemodialysis-associated xenobiotic that is less toxic than bisphenol A

    Clinical Kidney Journal, Vol. 14, Núm. 4, pp. 1147-1155

2018

  1. Targeting inflammation in diabetic nephropathy: a tale of hope

    Expert Opinion on Investigational Drugs, Vol. 27, Núm. 11, pp. 917-930

2017

  1. Bisfenol (A) una toxina a tener en cuenta en el enfermo renal en hemodiálisis

    Revista Colombiana de Nefrología, Vol. 4, Núm. 1, pp. 57-68

  2. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway

    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 10, pp. 207-222

2013

  1. Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice

    PLoS ONE, Vol. 8, Núm. 12

  2. Use of TOF-SIMS in vascular biology

    Methods in Molecular Biology, Vol. 1000, pp. 33-43

2011

  1. Animal models of cardiovascular diseases

    Journal of Biomedicine and Biotechnology, Vol. 2011

  2. Proteomic approach to the study of statin pleiotropy in kidney transplant patients

    Pharmacology, Vol. 87, Núm. 3-4, pp. 161-168

2010

  1. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes

    Diabetes, Vol. 59, Núm. 6, pp. 1292-1301

  2. Regulation of vascular and renal cells by common mediators in health and disease: Role of the renin-angiotensin system in the pathophysiology of hypertension and cardiovascular disease

    Cardiorenal Syndrome: Mechanisms, Risk and Treatment (Springer Milan), pp. 49-63

  3. Statins inhibit angiotensin II/smad pathway and related vascular fibrosis, by a TGF-β-independent process

    PLoS ONE, Vol. 5, Núm. 11

2008

  1. Cluster TOF-SIMS imaging: A new light for in situ metabolomics?

    Proteomics, Vol. 8, Núm. 18, pp. 3735-3745

  2. Proteomics in atherosclerosis

    Current Atherosclerosis Reports, Vol. 10, Núm. 3, pp. 209-215

2007

  1. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques

    European Journal of Pharmacology, Vol. 562, Núm. 1-2, pp. 119-129

  2. Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging

    Analyst, Vol. 132, Núm. 1, pp. 24-26

2006

  1. Modulación mediante tratamiento con atorvastatina y/o amlodipino del perfil de proteínas liberadas por placas ateroscleróticas humanas

    Clínica e investigación en arteriosclerosis, Vol. 18, Núm. 5, pp. 167-175

2005

  1. Quest for novel cardiovascular biomarkers by proteomic analysis

    Journal of Proteome Research, Vol. 4, Núm. 4, pp. 1181-1191

2004

  1. Análisis proteómico de monocitos circulantes humanos. Aplicacíon a pacientes con síndrome coronario agudo

    Investigacion Cardiovascular, Vol. 7, Núm. 1, pp. 1-18

  2. Isolation of circulating human monocytes with high purity for proteomic analysis

    Proteomics